PYC Therapeutics logo

PYC - PYC Therapeutics Share Price

A$0.15 0.0  3.5%

Last Trade - 2:44am

Sector
Healthcare
Size
Small Cap
Market Cap £260.9m
Enterprise Value £248.4m
Revenue £34.9k
Position in Universe 428th / 1838
Bullish
Bearish
Unlock PYC Revenue
Momentum
Relative Strength (%)
1m +2.28%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.81 0.000 2.76 0.048 0.000 0.063 -40.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, PYCTherapeutics Ltd revenues increased from A$0K to A$63K. Netloss increased 67% to A$6.8M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsPersonnel expenses - Balancing value increase from A$1.5Mto A$4.4M (expense), Stock-based Compensation in SGAincrease from A$115K to A$720K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PYC Revenue Unlock PYC Revenue

Net Income

PYC Net Income Unlock PYC Revenue

Normalised EPS

PYC Normalised EPS Unlock PYC Revenue

PE Ratio Range

PYC PE Ratio Range Unlock PYC Revenue

Dividend Yield Range

PYC Dividend Yield Range Unlock PYC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PYC EPS Forecasts Unlock PYC Revenue
Profile Summary

PYC Therapeutics Limited, formerly Phylogica Limited, is a pharmaceutical company. The Company is engaged combining its cell-penetrating peptides (CPP) technology with in ASOs to create a pipeline of drugs called CPP-ASOs. The Company intends to expand its pipeline to include other disease indications and therapeutic areas such as genetic neurodegenerative and liver diseases. Its pipeline products is Ocular, which is focused on treating retinitis pigmentosa and inherited retinal disease.

Directors
Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated October 9, 2001
Public Since March 30, 2005
No. of Shareholders: n/a
No. of Employees: 23
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 3,224,735,790
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PYC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PYC
Upcoming Events for PYC
Frequently Asked Questions for PYC Therapeutics
What is the PYC Therapeutics share price?

As of 2:44am, shares in PYC Therapeutics are trading at A$0.15, giving the company a market capitalisation of £260.9m. This share price information is delayed by 15 minutes.

How has the PYC Therapeutics share price performed this year?

Shares in PYC Therapeutics are currently trading at A$0.15 and the price has moved by 0.148k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the PYC Therapeutics price has moved by 0.128k% over the past year.

What are the analyst and broker recommendations for PYC Therapeutics?

Of the analysts with advisory recommendations for PYC Therapeutics, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for PYC Therapeutics is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will PYC Therapeutics next release its financial results?

PYC Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the PYC Therapeutics dividend yield?

PYC Therapeutics does not currently pay a dividend.

Does PYC Therapeutics pay a dividend?

PYC Therapeutics does not currently pay a dividend.

When does PYC Therapeutics next pay dividends?

PYC Therapeutics does not currently pay a dividend.

How do I buy PYC Therapeutics shares?

To buy shares in PYC Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of PYC Therapeutics?

Shares in PYC Therapeutics are currently trading at A$0.15, giving the company a market capitalisation of £260.9m.

Where are PYC Therapeutics shares listed? Where are PYC Therapeutics shares listed?

Here are the trading details for PYC Therapeutics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PYC
What kind of share is PYC Therapeutics?

Based on an overall assessment of its quality, value and momentum, PYC Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a PYC Therapeutics share price forecast 2021?

We were not able to load any forecast data for PYC Therapeutics.

How can I tell whether the PYC Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PYC Therapeutics. Over the past six months, the relative strength of its shares against the market has been 14.18%. At the current price of A$0.15, shares in PYC Therapeutics are trading at 7.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the PYC Therapeutics PE Ratio?

We were not able to find PE ratio data for PYC Therapeutics.

Who are the key directors of PYC Therapeutics?

PYC Therapeutics's management team is headed by:

Bernard Hockings - DRC
Natasha Santi - SEC
Rohan Hockings - OTH
Kevin Hart - CFO
Sahm Nasseri - OTH
Michael Williams - NED
Alan Tribe - CHM
Douglas Huey - CEO
May Orfali - OTH
Glenn Noronha - OTH
Who are the major shareholders of PYC Therapeutics?

Here are the top five shareholders of PYC Therapeutics based on the size of their shareholding:

Australian Land Pty. Ltd. Corporation
Percentage owned: 26.34% (835.3m shares)
Hockings (Bernard Edward Frederick) Individual Investor
Percentage owned: 8.29% (262.8m shares)
Sietsma Holdings Pty. Ltd. Corporation
Percentage owned: 5.27% (167.2m shares)
Masali Pty. Ltd. Corporation
Percentage owned: 3.68% (116.8m shares)
AP & CH Barton Superfunds Corporation
Percentage owned: 2.29% (72.6m shares)
Similar to PYC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.